- ►annals.org [PDF] BJ Veldt, EJ Heathcote, H Wedemeyer, J … - Annals of Internal Medicine, 2007 - Am Coll Physicians Background: Clinical outcomes of chronic hepatitis C infection in patients with
advanced fibrosis include liver failure, hepatocellular carcinoma, and death. ... Objective: To investigate whether sustained virologic response to ... Cited by 67 - Related articles - BL Direct - All 5 versions
S Bruno, T Stroffolini, M Colombo, S Bollani, … - HEPATOLOGY-BALTIMORE THEN ORLANDO-, 2007 - interscience.wiley.com This study has been presented in part at the 56th Annual Meeting of the American
Association for the Study of the Liver Diseases, San Francisco, CA, November
11-15, 2005. Potential conflict of interest: Nothing to report. § fax: ... Cited by 96 - Related articles - BL Direct - All 3 versions
P Pradat, HL Tillmann, S Sauleda, JH … - Journal of Viral Hepatitis, 2007 - phx1.medscape.com The aims of the study were to verify the long-term effect of time on viral
clearance in hepatitis C virus (HCV) patients and to find out factors possibly
associated with disease progression. A total of 1641 patients recruited ... Cited by 18 - Related articles - BL Direct - All 7 versions
- ►nih.gov AM Di Bisceglie, ML Shiffman, GT Everson, … - The New England journal of medicine, 2008 - nejm.highwire.org From Saint Louis University School of Medicine, St. Louis (AMD); the Virginia
Commonwealth University Medical Cen- ter, Richmond (MLS); the University of
Colorado School of Medicine, Denver (GTE); the Keck School of Medicine, ... Cited by 48 - Related articles - All 7 versions
ML Yu, CY Dai, JF Huang, NJ Hou, LP Lee, … - British Medical Journal, 2007 - gut.bmj.com Methods: Patients with HCV2 infection were randomised in a 1:2 ratio to either
16 weeks (n = 50) or 24 weeks (n = 100) of treatment with peginterferon -2a (180
µg/week) and weight-based ribavirin 1000–1200 mg/day, with a 24-week ... Cited by 86 - Related articles - BL Direct - All 5 versions
SL George, BR Bacon, EM Brunt, KL … - Hepatology, 2009 - umcn.nl One hundred fifty patients with sustained virologic response (SVR) after
treatment of chronic hepatitis C were enrolled in a long-term clinical follow-up
study; patients were followed for 5 years for liver-related outcomes and ... Cited by 10 - Related articles - View as HTML - All 4 versions
M Cornberg, J Hadem, E Herrmann, F … - Journal of hepatology, 2006 - Elsevier We initiated an open-label pilot study to investigate the efficacy of CIFN plus
ribavirin on viral kinetics, sustained virological response (SVR), and
histological response in hepatitis C non-responder patients. Seventy-seven ... Cited by 77 - Related articles - All 7 versions
G Taliani, G Gemignani, C Ferrari, A Aceti, D … - Gastroenterology, 2006 - Elsevier Background & Aims: Inadequate data are available about retreatment of
nonresponders to interferon (IFN) and ribavirin. Thus, this study evaluated the
efficacy and tolerability of a 48-week therapy with pegylated IFN-α-2b ... Cited by 46 - Related articles - All 18 versions
S Maylin, M Martinot–Peignoux, R Moucari, N … - Gastroenterology, 2008 - Elsevier Background & Aims: It is unclear whether hepatitis C virus (HCV) is eradicated
in patients with chronic hepatitis C who achieved a sustained virologic response
(SVR). Methods: In this long-term follow-up study, including chronic ... Cited by 39 - Related articles - All 35 versions
ML Yu, CY Dai, JF Huang, CF Chiu, YH Yang … - Hepatology, 2008 - jpkc.sysu.edu.cn Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is
peginterferon plus ribavirin for 48 weeks. We assessed whether treatment
duration of 24 weeks is as effective as standard treatment in HCV-1 ... Cited by 38 - Related articles - View as HTML - BL Direct - All 3 versions
